32034019|t|Antiviral therapy: Valacyclovir Treatment of Alzheimer's Disease (VALAD) Trial: protocol for a randomised, double-blind,placebo-controlled, treatment trial.
32034019|a|INTRODUCTION: After infection, herpes simplex virus-1 (HSV1) becomes latent in the trigeminal ganglion and can enter the brain via retrograde axonal transport. Recurrent reactivation of HSV1 may lead to neurodegeneration and Alzheimer's disease (AD) pathology. HSV1 (oral herpes) and HSV2 (genital herpes) can trigger amyloid beta-protein (Abeta) aggregation and HSV1 DNA is common in amyloid plaques. Anti-HSV drugs reduce Abeta and phosphorylated tau accumulation in cell-culture models. Cognitive impairment is greater in patients with HSV seropositive, and antiviral drugs show robust efficacy against peripheral HSV infection. Recent studies of electronic health records databases demonstrate that HSV infections increase dementia risk, and that antiviral medication treatment reduces this risk. The generic antiviral drug valacyclovir was superior to placebo in improving memory in a schizophrenia pilot trial but has not been tested in AD. METHODS AND ANALYSIS: In patients with mild AD who test positive for HSV1 or HSV2 serum antibodies, valacyclovir, repurposed as an anti-AD drug, will be compared with placebo (lactose pills) in 130 patients (65 valacyclovir and 65 placebo) in a randomised, double-blind, 78-week phase II proof-of-concept trial. Patients on valacyclovir, dose-titrated from 2 g to a targeted oral dose of 4 g daily, compared with placebo, are hypothesised to show smaller cognitive and functional decline, and, using 18F-Florbetapir positron emission tomography (PET) and 18F-MK-6240 PET imaging, to show less amyloid and tau accumulation, respectively. In the lumbar puncture subsample, cerebrospinal fluid acyclovir will be assayed to assess central nervous system valacyclovir penetration. ETHICS AND DISSEMINATION: The trial is being overseen by the New York State Psychiatric Institute Institutional Review Board (protocol 7537), the National Institute on Ageing, and the Data Safety Monitoring Board. Written informed consent is obtained for all subjects. Results will be disseminated via publication, clinicaltrials.gov, media and conferences. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov identifier (NCT03282916) Pre-results.
32034019	19	31	Valacyclovir	Chemical	MESH:D000077483
32034019	45	64	Alzheimer's Disease	Disease	MESH:D000544
32034019	66	71	VALAD	Disease	
32034019	188	210	herpes simplex virus-1	Species	10298
32034019	212	216	HSV1	Species	10298
32034019	343	347	HSV1	Species	10298
32034019	360	377	neurodegeneration	Disease	MESH:D019636
32034019	382	401	Alzheimer's disease	Disease	MESH:D000544
32034019	403	405	AD	Disease	MESH:D000544
32034019	418	422	HSV1	Species	10298
32034019	424	435	oral herpes	Disease	MESH:D013283
32034019	441	445	HSV2	Species	10310
32034019	447	461	genital herpes	Disease	MESH:D006558
32034019	497	502	Abeta	Gene	351
32034019	520	524	HSV1	Species	10298
32034019	542	557	amyloid plaques	Disease	MESH:D058225
32034019	564	567	HSV	Disease	MESH:C536395
32034019	581	586	Abeta	Gene	351
32034019	606	609	tau	Gene	4137
32034019	647	667	Cognitive impairment	Disease	MESH:D003072
32034019	682	690	patients	Species	9606
32034019	696	699	HSV	Disease	MESH:C536395
32034019	774	787	HSV infection	Disease	MESH:C536395
32034019	860	874	HSV infections	Disease	MESH:C536395
32034019	884	892	dementia	Disease	MESH:D003704
32034019	985	997	valacyclovir	Chemical	MESH:D000077483
32034019	1047	1060	schizophrenia	Disease	MESH:D012559
32034019	1100	1102	AD	Disease	MESH:D000544
32034019	1129	1137	patients	Species	9606
32034019	1148	1150	AD	Disease	MESH:D000544
32034019	1173	1177	HSV1	Species	10298
32034019	1204	1216	valacyclovir	Chemical	MESH:D000077483
32034019	1240	1242	AD	Disease	MESH:D000544
32034019	1280	1287	lactose	Chemical	MESH:D007785
32034019	1302	1310	patients	Species	9606
32034019	1315	1327	valacyclovir	Chemical	MESH:D000077483
32034019	1416	1424	Patients	Species	9606
32034019	1428	1440	valacyclovir	Chemical	MESH:D000077483
32034019	1559	1591	cognitive and functional decline	Disease	MESH:D003072
32034019	1604	1619	18F-Florbetapir	Chemical	MESH:C545186
32034019	1659	1663	18F-	Chemical	MESH:C000615276
32034019	1663	1670	MK-6240	Chemical	MESH:C000618291
32034019	1697	1704	amyloid	Disease	MESH:C000718787
32034019	1709	1712	tau	Gene	4137
32034019	1795	1804	acyclovir	Chemical	MESH:D000212
32034019	1854	1866	valacyclovir	Chemical	MESH:D000077483
32034019	1880	1904	ETHICS AND DISSEMINATION	Disease	MESH:D009103
32034019	Negative_Correlation	MESH:C000615276	MESH:D000077483
32034019	Negative_Correlation	MESH:C000618291	MESH:C000718787
32034019	Negative_Correlation	MESH:D000077483	MESH:C536395
32034019	Association	MESH:C000615276	4137
32034019	Association	MESH:C545186	4137
32034019	Negative_Correlation	MESH:D000077483	4137
32034019	Negative_Correlation	MESH:C545186	MESH:D000077483
32034019	Association	MESH:C000618291	4137
32034019	Negative_Correlation	MESH:C536395	351
32034019	Negative_Correlation	MESH:C000615276	MESH:C000718787
32034019	Negative_Correlation	MESH:C536395	4137
32034019	Positive_Correlation	MESH:D013283	351
32034019	Negative_Correlation	MESH:D000077483	MESH:C000718787
32034019	Negative_Correlation	MESH:D000077483	MESH:D000544
32034019	Negative_Correlation	MESH:C000618291	MESH:D000077483
32034019	Association	MESH:C545186	MESH:C000718787
32034019	Positive_Correlation	MESH:D006558	351
32034019	Negative_Correlation	MESH:D000077483	MESH:D003072

